Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.

Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.

The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.

Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.

The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.

Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.